EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid emergence of resistance to broad-spectrum direct antimicrobial activity of avibactam

Michelle Nägeli, Shade Rodriguez, Aimee Iradukunda, Abigail L Manson iD, Ashlee M Earl iD, Thea Brennan-Krohn iD

Microbiology Spectrum · 05.08.2025 · 13 (8)

DOI: 10.1128/spectrum.03241-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 05.08.2025. Verfasst von Michelle Nägeli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Anti-Bacterial Agents, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Avibactam (AVI) is a diazabicyclooctane (DBO) β-lactamase inhibitor used clinically in combination with ceftazidime. At concentrations higher than those typically achieved in vivo , it also has broad-spectrum direct antibacterial activity against Enterobacterales strains, including metallo-β-lactamase-producing isolates, mediated by inhibition of penicillin-binding protein 2 (PBP2). This activity has some mechanistic similarities to that of more potent novel DBOs (zidebactam and nacubactam) in late clinical development. We found that resistance to AVI emerged readily, with a mutation frequency of 2 × 10 −6 to 8 × 10 −5 . Whole-genome sequencing of resistant isolates revealed a heterogeneous mutational target that permitted bacterial survival and replication despite PBP2 inhibition, in line with prior studies of PBP2-targeting drugs. While such mutations are believed to act by upregulating the bacterial stringent response, we found a similarly high mutation frequency in bacteria deficient in components of the stringent response, although we observed a different set of mutations in these strains. Although avibactam-resistant strains had increased lag time, suggesting a fitness cost that might render them less problematic in clinical infections, there was no statistically significant difference in growth rates between susceptible and resistant strains. The finding of rapid emergence of resistance to avibactam as the result of a large and complex mutational target adds to our understanding of resistance to PBP2-targeting drugs and has potential implications for novel DBOs with potent direct antibacterial activity, which are being developed with the goal of expanding cell wall-active treatment options for multidrug-resistant gram-negative infections. IMPORTANCE Avibactam (AVI) is the first in a class of novel β-lactamase inhibitor antibiotics called diazabicyclooctanes (DBOs). In addition to its ability to inhibit bacterial β-lactamase enzymes that can destroy β-lactam antibiotics, we found that AVI had direct antibacterial activity, at concentrations higher than those used clinically, against even highly multidrug-resistant bacteria. This activity is the result of inhibition of the bacterial enzyme penicillin-binding protein 2 (PBP2). Resistance to other drugs that inhibit PBP2 occurs through mutations that involve upregulation of the bacterial “stringent response” to stress. We found that bacteria developed resistance to AVI at a high rate, as a result of mutations in stringent response genes. We also found that bacteria with impairments in the stringent response could still develop resistance to AVI through different mutations. Our findings indicate the importance of studying how resistance will emerge to newer, more potent DBOs in development and early clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Azabicyclo CompoundsAnti-Bacterial Agentsbeta-Lactamase InhibitorsMicrobial Sensitivity TestsHumansWhole Genome SequencingDrug Resistance, Multiple, BacterialMutationBacterial ProteinsPenicillin-Binding Proteinsbeta-Lactamases

Stichwörter der Autor:innen

antibiotic resistanceantimicrobial resistanceavibactamdiazabicyclooctanegram-negative bacteriapenicillin-binding proteins

Substanzen

Azabicyclo CompoundsavibactamAnti-Bacterial Agentsbeta-Lactamase InhibitorsBacterial ProteinsPenicillin-Binding Proteinsbeta-Lactamases

Autor:innen und Institutionen

  • Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Abigail L Manson, Ashlee M Earl, Thea Brennan-Krohn

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS

Zitieren

APA

Nägeli, M., Rodriguez, S., Iradukunda, A., Manson, A. L., Earl, A. M., & Brennan-Krohn, T. (2025). Rapid emergence of resistance to broad-spectrum direct antimicrobial activity of avibactam. Microbiology Spectrum, 13(8). https://doi.org/10.1128/spectrum.03241-24

Vancouver

Nägeli M, Rodriguez S, Iradukunda A, Manson AL, Earl AM, Brennan-Krohn T. Rapid emergence of resistance to broad-spectrum direct antimicrobial activity of avibactam. Microbiology Spectrum. 2025;13(8). doi:10.1128/spectrum.03241-24

BibTeX
@article{Ngeli2025,
  author = {Nägeli, Michelle and Rodriguez, Shade and Iradukunda, Aimee and Manson, Abigail L and Earl, Ashlee M and Brennan-Krohn, Thea},
  title = {Rapid emergence of resistance to broad-spectrum direct antimicrobial activity of avibactam},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {8},
  doi = {10.1128/spectrum.03241-24}
}
Kostenlos starten →